Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Meloxicam
Drug ID BADD_D01374
Description Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis.[A190189] With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is available in oral, transdermal, and intravenous formulations. It is a preferential COX-2 inhibitor, purportedly reducing the risk of adverse gastrointestinal tract effects, however, this is a topic of controversy.[A190198,A190201]
Indications and Usage Meloxicam is indicated for the symptomatic treatment of arthritis and osteoarthritis. In addition, it is indicated for the pauciarticular and polyarticular course of Juvenile Rheumatoid Arthritis (JRA) in patients aged 2 years old or above.[L11398] Off-label uses include the treatment of dental or post-surgical pain. In addition to the above, meloxicam has also been studied in the treatment of neuropathic pain. [A190189] Meloxicam, together with the local anesthetic [bupivacaine], is indicated for the production of postsurgical analgesia in adult patients for up to 72 hours following bunionectomy, open inguinal herniorrhaphy or total knee arthroplasty.[L34100]
Marketing Status approved; vet_approved
ATC Code M01AC06
DrugBank ID DB00814
KEGG ID D00969
MeSH ID D000077239
PubChem ID 54677470
TTD Drug ID D0G7FJ
NDC Product Code 72919-124; 80425-0041; 38779-2746; 53069-0790; 69237-004; 43602-623; 50090-5339; 51655-571; 55289-272; 63629-2019; 68788-1701; 70518-0171; 70518-0200; 70934-011; 70954-077; 71610-657; 71740-339; 51869-0007; 53747-006; 60592-994; 50268-526; 51655-731; 53002-2537; 60760-404; 61442-127; 63187-082; 63187-083; 70518-1630; 71610-516; 0615-8124; 72865-137; 76420-043; 49452-4402; 65862-097; 16571-776; 42708-093; 45865-360; 61442-126; 61919-434; 64380-715; 65841-050; 65841-051; 67296-1317; 67296-1460; 68071-2184; 68180-189; 68180-502; 68382-050; 68788-9418; 70518-1299; 71205-923; 71335-0406; 58118-1158; 60687-199; 60760-448; 60760-653; 67296-0823; 68788-7904; 69097-158; 70934-010; 71335-1956; 80425-0044; 51552-1377; 51869-0008; 58624-0430; 59349-0003; 70859-007; 42708-007; 51655-577; 63629-3328; 64380-716; 80425-0043; 53104-7574; 65862-098; 43063-395; 43353-979; 61919-469; 67296-1817; 68071-1919; 68180-501; 68462-140; 70518-2631; 71610-542; 0615-8040; 76282-152; 80425-0042; 80425-0083; 22365-116; 52119-003; 56125-750; 68225-112; 16571-777; 49999-869; 68382-051; 68462-141; 70518-3023; 71205-924; 71610-583; 76420-039; 17373-1157; 17373-1158; 35356-808; 43063-396; 43602-624; 51407-611; 53002-2535; 60760-419; 63629-3248; 68071-3030; 68071-4987; 68788-7726; 70954-076; 71335-1888; 71610-580; 80425-0045; 65862-223; 68981-032; 51655-177; 67296-0583; 68180-188; 71335-1618; 71610-544; 51927-0032; 43063-401; 50268-525; 67296-1250; 69097-159; 70518-1828; 71335-2080; 72865-138; 76282-153; 29300-124; 29300-125; 50090-0985; 50090-5861; 51407-610
UNII VG2QF83CGL
Synonyms Meloxicam | Miloxicam | Parocin | Mobic | Mobicox | Mobec | Masflex | Movicox | Reumoxicam | Uticox | Movalis
Chemical Information
Molecular Formula C14H13N3O4S2
CAS Registry Number 71125-38-7
SMILES CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Musculoskeletal stiffness15.03.05.027--Not Available
Inappropriate antidiuretic hormone secretion14.05.07.001; 05.03.03.0010.000016%Not Available
Haemorrhage24.07.01.0020.000087%Not Available
Gastrointestinal ulcer haemorrhage24.07.02.023; 07.04.04.0060.000032%Not Available
Colitis microscopic07.08.01.0110.000048%Not Available
Drug resistance08.06.01.0050.000087%Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
Inflammation10.02.01.089; 08.01.05.0070.000024%Not Available
Joint lock15.01.08.004--Not Available
Mental disorder19.07.01.0020.000035%Not Available
Amnestic disorder19.20.05.001; 17.03.02.0070.000024%Not Available
Disease progression08.01.03.0380.000103%
Drug intolerance08.06.01.0130.000032%Not Available
Renal impairment20.01.03.0100.000055%Not Available
Haemorrhagic diathesis24.07.01.020; 01.01.03.0030.000016%Not Available
Intestinal diaphragm disease07.13.01.0110.000079%Not Available
Tendon pain15.07.01.009--Not Available
Treatment failure08.06.01.0170.000062%Not Available
Oropharyngeal pain07.05.05.004; 22.12.03.016--
Acute kidney injury20.01.03.0160.000154%
Drug-induced liver injury12.03.01.044; 09.01.07.0230.000135%Not Available
Drug reaction with eosinophilia and systemic symptoms12.03.01.064; 23.03.05.005; 10.01.01.0210.000087%Not Available
Complication associated with device08.07.01.011--Not Available
Faeces pale07.01.03.005--Not Available
Gastric mucosal hypertrophy07.11.03.0060.000032%Not Available
Foot deformity15.10.03.005--Not Available
Small intestinal stenosis07.13.06.0080.000024%
Ischaemic gastritis24.04.08.017; 07.08.02.0060.000032%Not Available
Spinal pain17.10.01.020; 15.02.01.008; 08.01.08.030--Not Available
Sensitivity to weather change08.01.03.077--Not Available
The 9th Page    First    Pre   9 10    Next   Last    Total 10 Pages